<DOC>
	<DOC>NCT00821392</DOC>
	<brief_summary>This study was designed to evalute the efficacy and safety of Febuxostat after oral administration to patientd with gout in Korea</brief_summary>
	<brief_title>Phase III Trial of Febuxostat in Korea Gout Patients</brief_title>
	<detailed_description>This is a multi-center, randomized, double-blind, allopurinol and placebo controlled, parallel, 5 arms, dose response, bridging study of 4 weeks duration. If subjects pass the screening evaluation after submitting a signed informed consent, they will be randomly assigned to one of the five treatment regimens; febuxostat 40mg, 80mg, 120mg, placebo or allopurinol 300mg. Colchicine 0.6mg QDis given to minimize the risk of gout flares during the washout/run-in period and during the double study period.</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>&lt;Day 14&gt; 1. age :1885 years 2. female: either postmenopausal for at least 2 years, surgically sterile, or using a medically accepted means of contraception 3. female: negative serum pregnancy test 4. subjects who satisfy ARA (American Rheumatism Association) 5. subjects must have a renal function defined as: serum creatinine ≤ 1.5 mg/dL &lt;Day 1&gt; 1.serum urate level ≥8.0mg/dL 2.creatinine level ≤ 1.5mg/dL 3.subject continued to meet all inclusion and no exclusion criteria 1. women who are breastfeeding or pregnant 2. a history of xanthinuria 3. allopurinol intolerance 4. receiving thiazide diuretic therapy 5. secondary hyperuricemia 6. required &gt; 10mg/day of prednisone during the study stable dose(≤10mg/day), inhaled and intranasal steroids will be allowed. 7. concomitant therapy containing aspirin or other salicylates(systemic or topical, prescribed or nonprescribed) stable, low doses aspirin will be allowed(i.e. ≤325mg/day). 8. any change in hormone replacement therapy or oral contraceptive therapy within 3 months of the screening visit 9. alcohol intake≥ 14drinks/week alcohol abuse within 5 years or current excessive alcohol use was prohibited. 10. concomitant therapy with any uratelowering therapy 11. active liver disease or hepatic dysfunction : ALT, AST ≥1.5 ULN 12. subject was unable to take colchicine or contradictory to colchicine 13. a serum urate level &lt; 8.0mg/dL and not taking uric acid lowering therapy 14. rheumatoid arthritis or any active arthritis requiring for the medication treatment 15. a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the screening visit, or had taken any systemic cancer chemotherapy within 5 years prior to the screening visit 16. participated in another investigational trial within the 30days prior to the screening visit 17. any other significant medical condition as defined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>